Ads
related to: cancer, herceptin- Downloadable Resources
Access ENHERTU Downloadable
Resources For Your Patients.
- Efficacy & Safety Data
Learn More About The
Efficacy & Safety Data For ENHERTU.
- ENHERTU Dosing
Find ENHERTU Dosing & Admin
Resources For Your Practice.
- ENHERTU Information
Visit To Learn More About
ENHERTU For Your Practice.
- Watch MOA Videos
Watch Mechanism Of Action Videos
For ENHERTU. HCP Site.
- ENHERTU Resources
Find Helpful ENHERTU Resources
For Your Practice.
- Downloadable Resources
Search results
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoIt will be historic when it is no longer the first prescribed agent in HER2+ mBC and Enhertu may...
UCLA oncologist Dr. Dennis Slamon awarded Szent-Gy | Newswise
Newswise· 3 days agoDr. Dennis Slamon, a world-renowned oncologist and scientist whose groundbreaking research has...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 6 hours agoA New Top Biotech Stock Corcept Therapeutics is a newer addition to the list of leading biotech...
ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?
Pharmaceutical Technology via Yahoo Finance· 4 days agoARX788 is attempting to enter a crowded field, Enhertu (trastuzumab deruxtecan) is the standard of...
Astra's Enhertu breast cancer trial shows 'unprecedented' results
Reuters via Yahoo News· 5 days ago(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about...
ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision
FierceBiotech· 6 days agoAs zanidatamab awaits an FDA approval decision, Jazz Pharmaceuticals is sharing
...Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer - ALX...
Benzinga· 5 days agoEvorpacept in combination with PADCEV®, an approved antibody-drug conjugate ("ADC"), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt,
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks via Yahoo Finance· 3 days agoIn 2024, Teva expects Uzedy sales of approximately $80 million. Teva markets biosimilar versions of...
The Zacks Analyst Blog Highlights Roche, Wells Fargo, General Aerospace and Key Tronic
Zacks via Yahoo Finance· 2 days agoThe outlook for 2024 is ordinary as well. Competition from biosimilars for established cancer...
Ads
related to: cancer, herceptin